Expression of Immune Response Markers in Arab Patients With Lung Cancer | Zendy

Abdul Rahman Jazieh | Zendy; A. Bounedjar | Zendy; Hanaa Bamefleh | Zendy; Turki Alfayea | Zendy; Hatim Al-Maghraby | Zendy; Ayed Belarabi | Zendy; Wahiba Ouahioune | Zendy; Zoubir Derbouz | Zendy; Mohammad Alkaiyat | Zendy; Khaled Alkattan | Zendy; Moussab Damlaj | Zendy; Walid E. Khalbuss | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Expression of Immune Response Markers in Arab Patients With Lung Cancer

Author(s) -

Abdul Rahman Jazieh,

A. Bounedjar,

Hanaa Bamefleh,

Turki Alfayea,

Hatim Al-Maghraby,

Ayed Belarabi,

Wahiba Ouahioune,

Zoubir Derbouz,

Mohammad Alkaiyat,

Khaled Alkattan,

Moussab Damlaj,

Walid E. Khalbuss

Publication year - 2020

Publication title -

jco global oncology

Language(s) - English

Resource type - Journals

ISSN - 2687-8941

DOI - 10.1200/go.20.00107

Subject(s) - lung cancer , medicine , univariate analysis , cd8 , immunohistochemistry , tumor infiltrating lymphocytes , oncology , population , cancer , lymphocyte , odds ratio , pathology , multivariate analysis , immune system , immunology , immunotherapy , environmental health

Programmed death-ligand 1 (PD-L1) is a marker for checkpoint inhibitor use in the management of solid tumors, especially in non-small-cell lung cancer (NSCLC). Our study was aimed at determining the patterns of PD-L1 expression and cluster of differentiation 8 (CD8) immunostains in patients with NSCLC in the Arab population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research